Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : American Home Products AHP -- Ignore unavailable to you. Want to Upgrade?

To: Charles Tutt who wrote (114)	8/14/1998 6:22:00 PM
From: Henry Niman	Respond to of 169

It's a pain relief medication that doesn't lose effectiveness over time. I think that the largest targeted market is arthritis.

To: Charles Tutt who wrote (114)	8/22/1998 6:06:00 AM
From: Henry Niman	Respond to of 169

Relief of arthritic inflammation and pain relief will be the initial therapeutic indications for COX-2 inhibitors and the first couple of products could be launched sometime in 1H99. From the tone of the conference there appears to be some uncertainty about the timing of Searle's Celebra NDA filing, as well as, FDA requirements for an expedited review and for a superior safety claim versus NSAID's on the label. However, Celebra still appears to be the first product that could hit the market and be followed by Merck's Vioxx a few months later. There was also some debate about the edema side-effect (7-8% patients) of Vioxx at higher doses and the trade-off represented by its convenient once a day dosing versus Celebra's twice daily dose. A total of 6-8 companies are developing compounds with Searle and Merck in the lead. Other players who are in Phase II or earlier are: JNJ, GLX, ZEN, BMY, Roche Bioscience and possibly Abbott and Pfizer.